David B. Roberts' departure as President of Lemaitre Vascular Inc was reported, effective December 31, 2026; the filing names no successor. As of November 6, 2026, Lemaitre Vascular Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 14, 2026 to October 15, 2026, naming 3 departures (Form 8-K, October 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lemaitre Vascular Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lemaitre Vascular Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-14 to 2026-10-15. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Lemaitre Vascular Inc files it.
Also on the record for Lemaitre Vascular Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G, by First Trust Portfolios L.P. | 5.15% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by George W. LeMaitre | 6.4% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13G/A, by Conestoga Capital Advisors | 8.12% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by George W. LeMaitre | 7.43% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lemaitre Vascular Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Lemaitre Vascular Inc and the records around it.
Lemaitre Vascular Inc elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Conestoga Capital Advisors also filed stake reports on 6 other companies: Stevanato Group S.p.A. (Jan 2026), TRANSCAT INC (Jan 2026)
- First Trust Portfolios L.P. also filed stake reports on 105 other companies: First Trust Exchange-Traded Fund (Nov 2026), First Trust Exchange-Traded Fund IV (Nov 2026), First Trust Exchange-Traded Fund VIII (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Lemaitre Vascular Inc
Get an email when Lemaitre Vascular Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lemaitre Vascular Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lemaitre Vascular Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lemaitre Vascular Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-15 | Out | President | 2026-12-31 | 8-K, 2026-10-15 | |
| 2026-04-14 | Out | Director | 8-K, 2026-04-14 | ||
| 2026-04-14 | Out | Director | 8-K, 2026-04-14 |
Who leads Lemaitre Vascular Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: David B. Roberts, departure reported, effective 2026-12-31 (filed 2026-10-15). No successor is named in these filings.
- Director: Bridget Ross, departure reported (filed 2026-04-14). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Lemaitre Vascular Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at Lemaitre Vascular Inc, with the record behind each one.
Find candidates like President at Lemaitre Vascular IncEvery change, in the filing's words
Departing: David B. Roberts, President, effective 2026-12-31
(b) On October 9, 2026, David B. Roberts notified LeMaitre Vascular, Inc. (the "Company") of his intent to retire as an employee of the Company, including as its President, effective as of December 31, 2026.
- Mr. Roberts was reelected as a director at the Company's 2026 Annual Meeting of Stockholders for a term ending in 2029, and Mr. Roberts intends to continue to serve on the Company's Board of Directors following his retirement as President.
- The Company thanks Mr. Roberts for his 29 years of executive service and is pleased to retain his Board-level services going forward.
- These risks and uncertainties include risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov.
Departing: Bridget Ross, Director
(b) On April 8, 2026, Bridget Ross notified the Board of Directors (the "Board") of LeMaitre Vascular, Inc. (the "Company") of her intent not to stand for re-election as a Class II director of the Company at the Company's 2026 Annual Meeting of Stockholders to be held on June 2, 2026 (the "2026 Annual Meeting").
Departing: David B. Roberts, Director
In connection with such nomination, on April 9, 2026, Mr. Roberts notified the Board of his intent to resign as a Class I director at the conclusion of the 2026 Annual Meeting, contingent upon his election as a Class II director at such meeting.
- Ms. Ross will continue to serve as a director and a member of each committee of the Board to which she has been appointed until her current term expires at the 2026 Annual Meeting.
- Ms. Ross's decision not to stand for re-election is not related to any disagreement with the Company on any matter relating to the operations, policies, or practices of the Company.
- The Board thanks Ms. Ross for her service and contributions during her tenure.
- In order to rebalance the Board classes upon the expiration of Ms. Ross's current term at the 2026 Annual Meeting, the Board nominated David B. Roberts to stand for election as a Class II director at the 2026 Annual Meeting.
- Mr. Roberts's decision to conditionally resign as a Class I director is solely to facilitate his election as a Class II director at the 2026 Annual Meeting and is not a result of any disagreement with the Company on any matter relating to the operations, policies, or practices of the Company.
- Upon the effectiveness of Ms. Ross's departure, and assuming Mr. Roberts's election as a Class II director, at the conclusion of the Annual Meeting the Board will consist of seven members, designated as two Class I directors, two Class II directors, and three Class III directors.
Tools for this story
Each opens in a new tab, filled in for Lemaitre Vascular Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.